Increasing unusual put option volume: UNIT REN TSM LSI ALNY SSRM
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alnylam Pharmaceuticals (ALNY) PT Raised to $134 at BMO Capital; Makes Case for $165 Upside Scenario
September 21, 2017 3:40 PM EDTBMO Capital analyst Do Kim raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $134.00 (from $99.00) while maintaining an Outperform rating following strong APOLLO data.
"We believe an early restart of Fitusiran trials and positive Givosiran interim data (mid-2018) would enable shares to approach our $165 upside scenario," the analyst said.
... MoreAlnylam Pharmaceuticals (ALNY) PT Raised to $101 at Morgan Stanley
September 21, 2017 8:37 AM EDTMorgan Stanley raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $101.00 (from $50.00) while maintaining a Equalweight rating.
... MoreUPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg Thalmann
September 21, 2017 7:04 AM EDT(Updated - September 21, 2017 7:08 AM EDT)
(updated to add analyst comment)
Ladenburg Thalmann analyst Christopher James raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $146.00 (from $90.00) while maintaining a Buy rating.
The analyst is positive on the results from... More
